Chairpersons :

Avinash Deo, Vivek Agarwala, Amul Kapoor

Reviewer :

Amish Vora

1. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results

of the phase III multicentric italian short-HER study

Author: Pier Franco Conte

Citation: Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 501-501.ASCO

Abstract 501

2. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks

versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early

HER2- positive breast cancer (the SOLD study)

Author: Joensuu H.

Citation: SABCS Abstract GS3-04